Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 150

1.

4-Methylmethcathinone (mephedrone): neuropharmacological effects of a designer stimulant of abuse.

Hadlock GC, Webb KM, McFadden LM, Chu PW, Ellis JD, Allen SC, Andrenyak DM, Vieira-Brock PL, German CL, Conrad KM, Hoonakker AJ, Gibb JW, Wilkins DG, Hanson GR, Fleckenstein AE.

J Pharmacol Exp Ther. 2011 Nov;339(2):530-6. doi: 10.1124/jpet.111.184119. Epub 2011 Aug 2.

2.

Methamphetamine treatment during development attenuates the dopaminergic deficits caused by subsequent high-dose methamphetamine administration.

McFadden LM, Hoonakker AJ, Vieira-Brock PL, Stout KA, Sawada NM, Ellis JD, Allen SC, Walters ET, Nielsen SM, Gibb JW, Alburges ME, Wilkins DG, Hanson GR, Fleckenstein AE.

Synapse. 2011 Aug;65(8):771-7. doi: 10.1002/syn.20902. Epub 2011 Mar 21.

3.

Methamphetamine-induced dopaminergic deficits and refractoriness to subsequent treatment.

Hanson JE, Birdsall E, Seferian KS, Crosby MA, Keefe KA, Gibb JW, Hanson GR, Fleckenstein AE.

Eur J Pharmacol. 2009 Apr 1;607(1-3):68-73.

4.

Mechanisms underlying methamphetamine-induced dopamine transporter complex formation.

Hadlock GC, Baucum AJ 2nd, King JL, Horner KA, Cook GA, Gibb JW, Wilkins DG, Hanson GR, Fleckenstein AE.

J Pharmacol Exp Ther. 2009 Apr;329(1):169-74. doi: 10.1124/jpet.108.145631. Epub 2009 Jan 13.

5.

New insights into the mechanism of action of amphetamines.

Fleckenstein AE, Volz TJ, Riddle EL, Gibb JW, Hanson GR.

Annu Rev Pharmacol Toxicol. 2007;47:681-98. Review.

PMID:
17209801
6.

Methamphetamine administration reduces hippocampal vesicular monoamine transporter-2 uptake.

Rau KS, Birdsall E, Volz TJ, Riordan JA, Baucum AJ 2nd, Adair BP, Bitter R, Gibb JW, Hanson GR, Fleckenstein AE.

J Pharmacol Exp Ther. 2006 Aug;318(2):676-82. Epub 2006 May 10.

7.

Bupropion increases striatal vesicular monoamine transport.

Rau KS, Birdsall E, Hanson JE, Johnson-Davis KL, Carroll FI, Wilkins DG, Gibb JW, Hanson GR, Fleckenstein AE.

Neuropharmacology. 2005 Nov;49(6):820-30. Epub 2005 Jul 7.

PMID:
16005476
8.

Age-dependent methamphetamine-induced alterations in vesicular monoamine transporter-2 function: implications for neurotoxicity.

Truong JG, Wilkins DG, Baudys J, Crouch DJ, Johnson-Davis KL, Gibb JW, Hanson GR, Fleckenstein AE.

J Pharmacol Exp Ther. 2005 Sep;314(3):1087-92. Epub 2005 May 18.

9.

A single methamphetamine administration rapidly decreases vesicular dopamine uptake.

Brown JM, Riddle EL, Sandoval V, Weston RK, Hanson JE, Crosby MJ, Ugarte YV, Gibb JW, Hanson GR, Fleckenstein AE.

J Pharmacol Exp Ther. 2002 Aug;302(2):497-501.

10.

Methylenedioxymethamphetamine decreases plasmalemmal and vesicular dopamine transport: mechanisms and implications for neurotoxicity.

Hansen JP, Riddle EL, Sandoval V, Brown JM, Gibb JW, Hanson GR, Fleckenstein AE.

J Pharmacol Exp Ther. 2002 Mar;300(3):1093-100.

11.

Methamphetamine-induced rapid decrease in dopamine transporter function: role of dopamine and hyperthermia.

Metzger RR, Haughey HM, Wilkins DG, Gibb JW, Hanson GR, Fleckenstein AE.

J Pharmacol Exp Ther. 2000 Dec;295(3):1077-85.

12.

Differential effects of stimulants on monoaminergic transporters: pharmacological consequences and implications for neurotoxicity.

Fleckenstein AE, Gibb JW, Hanson GR.

Eur J Pharmacol. 2000 Oct 6;406(1):1-13. Review.

PMID:
11011026
13.

Differential effects of psychostimulants and related agents on dopaminergic and serotonergic transporter function.

Fleckenstein AE, Haughey HM, Metzger RR, Kokoshka JM, Riddle EL, Hanson JE, Gibb JW, Hanson GR.

Eur J Pharmacol. 1999 Oct 1;382(1):45-9.

PMID:
10556503
14.

3-4-Methylenedioxymethamphetamine-induced acute changes in dopamine transporter function.

Metzger RR, Hanson GR, Gibb JW, Fleckenstein AE.

Eur J Pharmacol. 1998 May 22;349(2-3):205-10.

PMID:
9671099
15.

Methamphetamine-induced rapid and reversible reduction in the activities of tryptophan hydroxylase and dopamine transporters: oxidative consequences?

Hanson GR, Gibb JW, Metzger RR, Kokoshka JM, Fleckenstein AE.

Ann N Y Acad Sci. 1998 May 30;844:103-7.

PMID:
9668668
16.

Methamphetamine treatment rapidly inhibits serotonin, but not glutamate, transporters in rat brain.

Kokoshka JM, Metzger RR, Wilkins DG, Gibb JW, Hanson GR, Fleckenstein AE.

Brain Res. 1998 Jul 13;799(1):78-83.

PMID:
9666084
17.

Methamphetamine-Induced Rapid and Reversible Reduction in the Activities of Tryptophan Hydroxylase and Dopamine Transporters: Oxidative Consequences?a.

Hanson GR, Gibb JW, Metzger RR, Kokoshka JM, Fleckenstein AE.

Ann N Y Acad Sci. 1998 May;844(1):103-107. doi: 10.1111/j.1749-6632.1998.tb08225.x.

PMID:
29090817
18.

Role of endogenous dopamine in the neurochemical deficits induced by methcathinone.

Gygi MP, Fleckenstein AE, Gibb JW, Hanson GR.

J Pharmacol Exp Ther. 1997 Dec;283(3):1350-5.

19.

Exacerbation of methamphetamine-induced neurochemical deficits by melatonin.

Gibb JW, Bush L, Hanson GR.

J Pharmacol Exp Ther. 1997 Nov;283(2):630-5.

20.

Oxygen radicals diminish dopamine transporter function in rat striatum.

Fleckenstein AE, Metzger RR, Beyeler ML, Gibb JW, Hanson GR.

Eur J Pharmacol. 1997 Sep 3;334(1):111-4.

PMID:
9346337
21.

Psychostimulants and neuropeptide response.

Hanson GR, Wagstaff JD, Merchant K, Gibb JW.

Adv Pharmacol. 1998;42:1014-6. No abstract available.

PMID:
9328070
22.
23.

Rapid and reversible effects of methamphetamine on dopamine transporters.

Fleckenstein AE, Metzger RR, Wilkins DG, Gibb JW, Hanson GR.

J Pharmacol Exp Ther. 1997 Aug;282(2):834-8.

24.

Methamphetamine-induced decrease in tryptophan hydroxylase activity: role of 5-hydroxytryptaminergic transporters.

Fleckenstein AE, Beyeler ML, Jackson JC, Wilkins DG, Gibb JW, Hanson GR.

Eur J Pharmacol. 1997 Apr 18;324(2-3):179-86.

PMID:
9145769
25.

A rapid and reversible change in dopamine transporters induced by methamphetamine.

Fleckenstein AE, Metzger RR, Gibb JW, Hanson GR.

Eur J Pharmacol. 1997 Apr 4;323(2-3):R9-10.

PMID:
9128855
26.
27.

Neurotoxicity of amphetamines and their metabolites.

Gibb JW, Johnson M, Elayan I, Lim HK, Matsuda L, Hanson GR.

NIDA Res Monogr. 1997;173:128-45. Review. No abstract available.

PMID:
9260187
28.

Comparison of neurotensin responses to MDL 100,907, a selective 5HT2A antagonist, with clozapine and haloperidol.

Hanson GR, Bush LG, Taylor VL, Gibb JW, Davis K, Schmidt CJ.

Brain Res Bull. 1997;42(3):211-9.

PMID:
8995332
29.
30.

Mechanisms for tolerance to methamphetamine effects.

Gygi MP, Gygi SP, Johnson M, Wilkins DG, Gibb JW, Hanson GR.

Neuropharmacology. 1996 Jun;35(6):751-7.

PMID:
8887984
31.
32.

Methcathinone: an initial study of its effects on monoaminergic systems.

Gygi MP, Gibb JW, Hanson GR.

J Pharmacol Exp Ther. 1996 Mar;276(3):1066-72.

PMID:
8786536
33.

Body temperature effect on methylenedioxymethamphetamine-induced acute decrease in tryptophan hydroxylase activity.

Che S, Johnson M, Hanson GR, Gibb JW.

Eur J Pharmacol. 1995 Dec 7;293(4):447-53.

PMID:
8748698
34.

Response of extrapyramidal and limbic neurotensin systems to phencyclidine treatment.

Hanson GR, Midgley LP, Bush LG, Gibb JW.

Eur J Pharmacol. 1995 May 15;278(2):167-73.

PMID:
7672001
35.

The role of NMDA receptor systems in neuropeptide responses to stimulants of abuse.

Hanson GR, Singh N, Merchant K, Johnson M, Gibb JW.

Drug Alcohol Depend. 1995 Feb;37(2):107-10.

PMID:
7758400
36.

Endogenous neurotensin antagonizes methamphetamine-enhanced dopaminergic activity.

Wagstaff JD, Bush LG, Gibb JW, Hanson GR.

Brain Res. 1994 Dec 5;665(2):237-44.

PMID:
7895059
37.

Effect of neonatal hypoxia-ischemia on nigro-striatal dopamine receptors and on striatal neuropeptide Y, dynorphin A and substance P concentrations in rats.

Johnson M, Hanson GR, Gibb JW, Adair J, Filloux F.

Brain Res Dev Brain Res. 1994 Nov 18;83(1):109-18.

PMID:
7535199
38.

Role of the 5-HT2 receptor in the methamphetamine-induced neurochemical alterations.

Johnson M, Sonsalla PK, Letter AA, Hanson GR, Gibb JW.

J Pharmacol Exp Ther. 1994 Jul;270(1):97-103.

PMID:
7913500
39.
40.

Dynamic dopaminergic regulation of neuropeptide Y systems in discrete striatal and accumbens regions.

Midgley LP, Wagstaff JD, Singh NA, Bush LG, Gibb JW, Hanson GR.

Eur J Pharmacol. 1994 Jan 14;251(2-3):191-9.

PMID:
7908639
41.

Effects of nimodipine on the amphetamine- and methamphetamine-induced decrease in tryptophan hydroxylase activity.

Elkins KW, Gibb JW, Hanson GR, Wilkins DG, Johnson M.

Eur J Pharmacol. 1993 Dec 21;250(3):395-402.

PMID:
8112400
42.
43.

Differential regulation of neuropeptide Y systems in limbic structures of the rat.

Midgley LP, Bush LG, Gibb JW, Hanson GR.

J Pharmacol Exp Ther. 1993 Nov;267(2):707-13.

PMID:
8246145
45.

Short-term effects of 2,4,5-trihydroxyamphetamine, 2,4,5-trihydroxymethamphetamine and 3,4-dihydroxymethamphetamine on central tryptophan hydroxylase activity.

Elayan I, Gibb JW, Hanson GR, Lim HK, Foltz RL, Johnson M.

J Pharmacol Exp Ther. 1993 May;265(2):813-8.

PMID:
8496826
46.

Mechanisms mediating biogenic amine deficits induced by amphetamine and its congeners.

Gibb JW, Johnson M, Stone DM, Hanson GR.

NIDA Res Monogr. 1993;136:226-36; discussion 236-41. Review. No abstract available.

PMID:
7904727
48.

Characterization of phencyclidine-induced effects on neuropeptide Y systems in the rat caudate-putamen.

Midgley LP, Bush LG, Gibb JW, Hanson GR.

Brain Res. 1992 Oct 9;593(1):89-96.

PMID:
1360868
49.

Response of monoaminergic and neuropeptide systems to 4-methylaminorex: a new stimulant of abuse.

Hanson GR, Bunker CF, Johnson M, Bush L, Gibb JW.

Eur J Pharmacol. 1992 Aug 6;218(2-3):287-93.

PMID:
1358636
50.

Effect of flunarizine and nimodipine on the decrease in tryptophan hydroxylase activity induced by methamphetamine and 3,4-methylenedioxymethamphetamine.

Johnson M, Mitros K, Stone DM, Zobrist R, Hanson GR, Gibb JW.

J Pharmacol Exp Ther. 1992 May;261(2):586-91.

PMID:
1374469

Supplemental Content

Support Center